We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
+2.11%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$66.4M
AUM Growth
+$8.29M
Cap. Flow
+$122M
Cap. Flow %
183.83%
Top 10 Hldgs %
32.21%
Holding
297
New
108
Increased
49
Reduced
51
Closed
72

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$3.53M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$2.94M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$2.18M
4
ARAV
Aravive, Inc. Common Stock
ARAV
+$1.54M
5
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$1.37M

Top Sells

Rank Stock Value
1
GIS icon
General Mills
GIS
+$2.52M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$2.31M
3
AMGN icon
Amgen
AMGN
+$2.08M
4
ABT icon
Abbott
ABT
+$1.72M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$1.56M

Sector Composition

Rank Sector Weight
1 Healthcare 41.81%
2 Consumer Discretionary 7.1%
3 Consumer Staples 6.25%
4 Communication Services 0.99%
5 Materials 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBT
276
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-20,000
Closed -$30K
GBT
277
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-1,805
Closed -$49K
GBT
278
PUT
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-20,000
Closed -$54K
MNK
279
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-10,000
Closed -$448K
MNK
280
PUT
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-7,700
Closed -$8K
PTLA
281
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-46,100
Closed -$395K
PTLA
282
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-41,187
Closed -$2.31M
PTLA
283
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-122,300
Closed -$36K
AGN
284
CALL
DELISTED
Allergan plc
AGN
– –
-7,500
Closed -$46K
AGN
285
PUT
DELISTED
Allergan plc
AGN
– –
-12,000
Closed -$16K
AKS
286
CALL
DELISTED
AK Steel Holding Corp
AKS
– –
-20,000
Closed -$2K
MDCO
287
DELISTED
Medicines Co
MDCO
– –
-16,931
Closed -$644K
MDCO
288
PUT
DELISTED
Medicines Co
MDCO
– –
-17,000
Closed -$295K
IPCI
289
CALL
DELISTED
Intellipharmaceuticals International Inc.
IPCI
– –
-7,200
Closed -$23K
PF
290
DELISTED
Pinnacle Foods, Inc.
PF
– –
-7,100
Closed -$421K
WFM
291
CALL
DELISTED
Whole Foods Market Inc
WFM
– –
-21,400
Closed -$12K
KATE
292
CALL
DELISTED
Kate Spade & Company
KATE
– –
-50,400
Closed -$6K
KATE
293
DELISTED
Kate Spade & Company
KATE
– –
-300
Closed -$6K
DISH
294
CALL
DELISTED
DISH Network Corp.
DISH
– –
-24,300
Closed -$17K
NIHD
295
DELISTED
NII Holdings, Inc. Common Stock
NIHD
– –
-12,500
Closed -$10K
CELG
296
DELISTED
Celgene Corp
CELG
– –
-5,000
Closed -$649K
CELG
297
PUT
DELISTED
Celgene Corp
CELG
– –
-5,000
Closed -$13K
8 9 10 11
12

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q3 2017 Portfolio in Review

As of Q3 2017, FT Options held 297 positions worth $66.4M, up 14% from $58.1M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

FT Options deployed $122M of net new capital in Q3 2017, opening 108 new positions and adding to 49 existing holdings. Its largest new stake was Incyte: 27,887 shares worth $3.26M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 38% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

On the sell side, the largest reduction was General Mills, an estimated $2.52M trimmed.

  • FT Options's largest Q3 2017 buy was Incyte: 27,887 shares worth $3.26M.
  • FT Options added most to Sio Gene Therapies Inc. Common Stock in Q3 2017, an estimated $1.37M increase.
  • FT Options's biggest Q3 2017 reduction was General Mills, cutting an estimated $2.52M.
  • FT Options fully exited Portola Pharmaceuticals, Inc. in Q3 2017, selling an estimated $2.31M.
  • FT Options's ten largest holdings make up 32% of its $66.4M portfolio in Q3 2017.
  • FT Options opened 108 new positions and closed 72 in Q3 2017.
  • FT Options's portfolio value rose 14% quarter-over-quarter to $66.4M.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.